Cargando…
Correction to: MYL-1402O: A Bevacizumab Biosimilar
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217870/ https://www.ncbi.nlm.nih.gov/pubmed/35437710 http://dx.doi.org/10.1007/s11523-022-00882-1 |
| _version_ | 1784731753184755712 |
|---|---|
| author | Lee, Arnold |
| author_facet | Lee, Arnold |
| author_sort | Lee, Arnold |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9217870 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92178702022-06-24 Correction to: MYL-1402O: A Bevacizumab Biosimilar Lee, Arnold Target Oncol Correction Springer International Publishing 2022-04-18 2022 /pmc/articles/PMC9217870/ /pubmed/35437710 http://dx.doi.org/10.1007/s11523-022-00882-1 Text en © Springer Nature 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Correction Lee, Arnold Correction to: MYL-1402O: A Bevacizumab Biosimilar |
| title | Correction to: MYL-1402O: A Bevacizumab Biosimilar |
| title_full | Correction to: MYL-1402O: A Bevacizumab Biosimilar |
| title_fullStr | Correction to: MYL-1402O: A Bevacizumab Biosimilar |
| title_full_unstemmed | Correction to: MYL-1402O: A Bevacizumab Biosimilar |
| title_short | Correction to: MYL-1402O: A Bevacizumab Biosimilar |
| title_sort | correction to: myl-1402o: a bevacizumab biosimilar |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217870/ https://www.ncbi.nlm.nih.gov/pubmed/35437710 http://dx.doi.org/10.1007/s11523-022-00882-1 |
| work_keys_str_mv | AT leearnold correctiontomyl1402oabevacizumabbiosimilar |